U.S. markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
135.70+2.78 (+2.09%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
Previous Close132.92
Open133.68
Bid130.00 x 800
Ask144.00 x 800
Day's Range131.63 - 137.65
52 Week Range119.29 - 178.41
Volume442,240
Avg. Volume518,634
Market Cap15.951B
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-7.55
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est174.72
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Alnylam Announces New Advances in ATTR Amyloidosis Program
    Business Wire

    Alnylam Announces New Advances in ATTR Amyloidosis Program

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has started a clinical study of a biannual dosing regimen of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis. The study is being conducted during a randomized treatment extension (RTE) period in the HELIOS-A Phase 3 study, and will characterize the safety, efficacy, and TTR reduction of a 50 mg biannual dosing regimen of subcutaneously administered vutrisiran in patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy. In addition, the Company announces today advancement of a new pre-clinical ATTR amyloidosis program aimed at achieving highly potent and reversible TTR reduction of over 90 percent with an annual subcutaneous dosing regimen.

  • Alnylam to Webcast Presentations at Upcoming May Investor Conferences
    Business Wire

    Alnylam to Webcast Presentations at Upcoming May Investor Conferences

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences which are being held virtually:

  • Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
    Business Wire

    Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive early results on clinical outcome measures from the 12-month analysis of ILLUMINATE-A Phase 3 study of OXLUMO® (lumasiran), an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – for the treatment of primary hyperoxaluria type 1 (PH1). These data were presented at the American Society of Pediatric Nephrology (ASPN)/Pediatric Academic Societies (PAS) virtual meeting being held on April 30–May 4, 2021.